Brand Name : Mylovasc - 5 Tablets
Generic Name : S-Amlodipine Besilate Tablets 5 mg
Module - 1

APPENDIX 2

1.3.1 Summary of Product Characteristics (SmPC)

Factory: UNIT 1: 13, S.V. KOIL STREET, MADHAVARAM, CHENNAI-600 060, INDIA. PHONE: +044-25530329/25531965, Email:factory@bafnapharma.com
UNIT-II : 147, Madhavaram Redhills High Road, Grantlyon Village, Vadakarai Post, Chennai-600 052. Phone:+044-26322900, E mail: fatory1@bafnapharma.com

Brand Name : Mylovasc - 5 Tablets
Generic Name : S-Amlodipine Besilate Tablets 5 mg
Module - 1

1.3.1 Summary of product characteristics (SmPC)

1.1) **Name of the Finished Pharmaceutical Product** : Mylovasc-5 Tablets
(S-Amlodipine Besilate Tablets 5 mg)

1.2) Strength : 5 mg

1.3) Pharmaceutical Form : Oral Uncoated Tablets

Factory: UNIT 1: 13, S.V. KOIL STREET, MADHAVARAM, CHENNAI-600 060, INDIA. PHONE: +044-25530329/25531965, Email:factory@bafnapharma.com
UNIT-II : 147, Madhavaram Redhills High Road, Grantlyon Village, Vadakarai Post, Chennai-600 052. Phone:+044-26322900, E mail: fatory1@bafnapharma.com

REGD. OFFICE:"BAFNA TOWERS" 299, THAMBU CHETTY STREET, CHENNAI-600 001, INDIA.
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, email: info@bafnapharma.com, Website, www.bafnapharma.com
CIN : L24294 TN1995PLC030698

Brand Name : Mylovasc - 5 Tablets
Generic Name : S-Amlodipine Besilate Tablets 5 mg
Module - 1

1. Qualitative And Quantitative Composition

Each uncoated tablet contains:

S-Amlodipine Besilate is equivalent to S-Amlodipine 5 mg

UNIT FORMULA

Sr. No.	Ingredients	Specification	Qty / Tablet (mg)	% Overages	Reason for inclusion
Active					
1	S-Amlodipine Besilate*	MS	6.950	Nil	Active
Excipients					
2	Microcrystalline Cellulose (PH 102) **	BP	137.226	Nil	Lubricant
3	Sodium Starch Glycolate (Type-A)	BP	3.840	Nil	Disintegrant
4	Croscarmellose Sodium	BP	7.680	Nil	Disintegrant
5	Crospovidone (polyplasdone XL – 10)	BP	1.216	Nil	Binder
6	Sodium Acid Citrate	BP	0.128	Nil	Preservative
7	Colloidal Anhydrous Silica	BP	0.400	Nil	Glidant
8	Magnesium Stearate	BP	2.560	Nil	Lubricant

Note:

*** 6.950 mg of S-Amlodipine Besilate MS equivalent to S-Amlodipine 5 mg**

*Actual quantity of S-Amlodipine Besilate MS to be dispensed is based on actual % purity of S-Amlodipine Besilate MS from the Batch formula worksheet as per subsequent calculation.

** Quantity of Microcrystalline Cellulose BP (PH 102) should adjust to the target weight as per the calculation shown in the Batch formula Worksheet.

Target weight per uncoated tablet : 160.000mg

Factory: UNIT 1: 13, S.V. KOIL STREET, MADHAVARAM, CHENNAI-600 060, INDIA. PHONE: +044-25530329/25531965, Email:factory@bafnapharma.com
UNIT-II : 147, Madhavaram Redhills High Road, Grantlyon Village, Vadakarai Post, Chennai-600 052. Phone:+044-26322900, E mail: fatory1@bafnapharma.com

Brand Name : Mylovasc - 5 Tablets
Generic Name : S-Amlodipine Besilate Tablets 5 mg
Module - 1

3. Pharmaceutical Form: Uncoated Tablets.

4. Clinical Particulars:

4.1Therapeutic Indications:
- Essential hypertension

- Chronic stable and vasospastic anginal pectoris

4.2 Posology and method of administration:
Usual Adult Amlodipine Dose for Hypertension:

Initial dose: 5 mg orally once a day

Maintenance dose: 5 to 10 mg orally once a day

Small or fragile patients may be started on 2.5 mg orally once a day.

Usual Adult Amlodipine Dose for Angina Pectoris:

Chronic stable or vasospastic angina, or angio graphically documented coronary artery disease in patients without heart failure or an ejection fraction less than 40%: 5 to 10 mg orally once a day

Most patients with chronic stable or vasospastic angina require 10 mg for adequate effect. In clinical studies, most patients with coronary artery disease required 10 mg.

Usual Adult Amlodipine Dose for Coronary Artery Disease:

Chronic stable or vasospastic angina, or angiographically documented coronary artery disease in patients without heart failure or an ejection fraction less than 40%: 5 to 10 mg orally once a day

Most patients with chronic stable or vasospastic angina require 10 mg for adequate effect. In clinical studies, most patients with coronary artery disease required 10 mg.

Usual Geriatric Amlodipine Dose for Hypertension:

Initial dose: 2.5 mg orally once a day

Maintenance dose: 2.5 to 10 mg orally once a day

Factory: UNIT 1: 13, S.V. KOIL STREET, MADHAVARAM, CHENNAI-600 060, INDIA. PHONE: +044-25530329/25531965, Email:factory@bafnapharma.com
UNIT-II : 147, Madhavaram Redhills High Road, Grantlyon Village, Vadakarai Post, Chennai-600 052. Phone:+044-26322900, E mail: fatory1@bafnapharma.com

Usual Geriatric Dose for Angina Pectoris:

Chronic stable or vasospastic angina: 5 to 10 mg orally once a day

The lower dose is recommended in the elderly; however, most patients require 10 mg for adequate effect.

Usual Pediatric Dose for Hypertension:

6 to 17 years: 2.5 mg to 5 mg orally once a day

Doses in excess of 5 mg daily have not been studied in pediatric patients.

4.3 Contraindications:

Hypersensitivity to dihydropyridines, amlodipine or to any of the excipients.

Amlodipine should not be used in cardiogenic shock, clinically significant aortic stenosis, unstable angina (excluding Prinzmetal's angina). Pregnancy and lactation.

4.4 Special warning and precaution for use:

Use in patients with heart failure:

In a long term, placebo controlled study, in patients with NYHA III and IV heart failure of nonischaemic aetiology, amlodipine was associated with increased reports of pulmonary oedema despite no significant difference in the incidence of worsening heart failure as compared to placebo.

Use in patients with impaired hepatic function

As with all calcium antagonists, amlodipine's half-life is prolonged in patients with impaired liver function and dosage recommendations have not been established. The drug should therefore be administered with caution in these patients.

There are no data to support the use of amlodipine alone, during or within one month of a myocardial infarction. The safety and efficacy of amlodipine in hypertensive crisis has not been established.

Factory: UNIT 1: 13, S.V. KOIL STREET, MADHAVARAM, CHENNAI-600 060, INDIA. PHONE: +044-25530329/25531965, Email:factory@bafnapharma.com
UNIT-II : 147, Madhavaram Redhills High Road, Grantlyon Village, Vadakarai Post, Chennai-600 052. Phone:+044-26322900, E mail: fatory1@bafnapharma.com

Brand Name : Mylovasc - 5 Tablets
Generic Name : S-Amlodipine Besilate Tablets 5 mg
Module - 1

4.5 Interaction with other medicinal products and other forms of interaction:

Amlodipine has been safely administered with thiazide diuretics, alpha blockers, beta blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual glyceryl trinitrate, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycaemic drugs.

In vitro data from studies with human plasma, indicate that amlodipine has no effect on protein binding of digoxin, phenytoin, warfarin or indomethacin.

Consumption of grapefruit/grapefruit juice should be avoided while taking amlodipine. The intake of grapefruit juice may result in increased plasma amlodipine concentrations, which may enhance the blood pressure lowering effects of amlodipine. This interaction has been observed with other dihydropyridine calcium antagonists and represents a class effect.

Special Studies: Effect of other agents on amlodipine

Cimetidine: Co-administration of amlodipine with cimetidine did not alter the pharmacokinetics of amlodipine.

Sildenafil: When amlodipine and sildenafil were used in combination, each agent independently exerted its own blood pressure lowering effect.

Special Studies: Effect of amlodipine on other agents

Atorvastatin: Co-administration of multiple 10 mg doses of amlodipine with 80mg of atorvastatin resulted in no significant change in the steady state pharmacokinetic parameters of atrovastatin.

Digoxin: Co-administration of amlodipine with digoxin did not change serum digoxin levels or digoxin renal clearance in normal volunteers.

Warfarin: In healthy male volunteers, the co-administration of amlodipine does not significantly alter the effect of warfarin on prothrombin response time. Co-administration of amlodipine with warfarin did not change the warfarin prothrombin response time.

Factory: UNIT 1: 13, S.V. KOIL STREET, MADHAVARAM, CHENNAI-600 060, INDIA. PHONE: +044-25530329/25531965, Email:factory@bafnapharma.com
UNIT-II : 147, Madhavaram Redhills High Road, Grantlyon Village, Vadakarai Post, Chennai-600 052. Phone:+044-26322900, E mail: fatory1@bafnapharma.com

Ciclosporin: Pharmacokinetic studies with ciclosporin have demonstrated that amlodipine does not significantly alter the pharmacokinetics of ciclosporine.

Drug/Laboratory test interactions: None known.

4.6 Pregnancy and Lactation:

Pregnancy:

Although some dihydropyridine compounds have been found to be teratogenic in animals, data in the rat and rabbit for amlodipine provide no evidence for a teratogenic effect. There is, however, no clinical experience with the preparation in pregnancy. Accordingly, amlodipine should not be administered during pregnancy or to women of childbearing potential unless effective contraception is used.

Lactation:

Although some dihydropyridine compounds have been found to be teratogenic in animals, data in the rat and rabbit for amlodipine provide no evidence for a teratogenic effect. There is, however, no clinical experience with the preparation in lactation. Accordingly, amlodipine should not be administered during lactation.

4.7 Effects on the ability to drive and use machines:

Clinical experience with amlodipine indicates that therapy is unlikely to impair a patient's ability to drive or use machinery. In patients suffering from dizziness, headache, fatigue or nausea the ability to react may be impaired.

4.8 Undesirable effects:

The frequencies mentioned are subdivided on categories according to system organ class and frequency to following percentages:

Very common: more than 10%

Common: 10% or less, but more than 1%

Uncommon: 1%, or less, but more than 0,1%,

Rare: 0,1 % or less, but more than 0,01%

Factory: UNIT 1: 13, S.V. KOIL STREET, MADHAVARAM, CHENNAI-600 060, INDIA. PHONE: +044-25530329/25531965, Email:factory@bafnapharma.com
UNIT-II : 147, Madhavaram Redhills High Road, Grantlyon Village, Vadakarai Post, Chennai-600 052. Phone:+044-26322900, E mail: fatory1@bafnapharma.com

Very rare: 0,01% and less (this includes isolated reports).

The most commonly reported side effects of amlodipine are headache, oedema, rash, fatigue, nausea, flushing and dizziness.

Other reported side effects are:

Blood and the lymphatic system disorders:

Very rare: thrombocytopenia, leucocytopenia

Immune system disorders

Very rare: allergic reaction

Metabolic and nutrition disorders

Very rare: hyperglycaemia

Psychiatric disorders

Uncommon: mood changes, insomnia

Nervous system disorders

Common: somnolence, dizziness, headache

Uncommon: tremor, taste perversion, syncope, hypoaesthesia, paraesthesia

Very rare: peripheral neuropathy

Eye disorders

Uncommon: visual disturbances

Ear and Labyrinth disorders

Uncommon: tinnitus

Cardiac disorders

Common: Palpitations

Rare: syncope

Very rare: Myocardial infarction, arrhythmia, ventricular tachycardia and atrial fibrillation

Vascular disorders

Common: flushing

Factory: UNIT 1: 13, S.V. KOIL STREET, MADHAVARAM, CHENNAI-600 060, INDIA. PHONE: +044-25530329/25531965, Email:factory@bafnapharma.com
UNIT-II : 147, Madhavaram Redhills High Road, Grantlyon Village, Vadakarai Post, Chennai-600 052. Phone:+044-26322900, E mail: fatory1@bafnapharma.com

Uncommon: hypotension

Very rare: vasculitis

Respiratory, thoracic and mediastinal disorders

Uncommon: dyspnoea, rhinitis

Very rare: coughing

Gastrointestinal disorders

Common: Abdominal pain

Uncommon: Vomiting, dyspepsia, altered bowel habits, dry mouth

Very rare: pancreatitis, gastritis, gingival hyperplasia

Hepato - biliary disorders:

Very rare: abnormal liver function tests (mostly consistent with cholestasis), hepatitis, jaundice

Skin and subcutaneous tissue disorders

Uncommon: alopecia, pruritus, purpura, skin discolouration, increased sweating, rash

Very rare: erythema multiforme, angioedema and urticaria

Musculoskeletal, connective tissue and bone disorders

Uncommon: myalgia, arthralgia, muscle cramps and back pain

Renal and urinary disorders

Uncommon: increased urinary frequency, micturition disorder, nocturia

Reproductive system and breast disorders

Uncommon: impotence, gynaecomastia

General disorders and administration site conditions

Common: oedema, fatigue

Uncommon: chest pain, asthenia, pain, malaise,

Investigations

Uncommon: increase or decrease in weight

Factory: UNIT 1: 13, S.V. KOIL STREET, MADHAVARAM, CHENNAI-600 060, INDIA. PHONE: +044-25530329/25531965, Email:factory@bafnapharma.com
UNIT-II : 147, Madhavaram Redhills High Road, Grantlyon Village, Vadakarai Post, Chennai-600 052. Phone:+044-26322900, E mail: fatory1@bafnapharma.com

4.9 Overdose

Available data suggest that gross over dosage could result in excessive peripheral vasodilatation and possibly reflex tachycardia. Marked and probably prolonged systemic hypotension up to and including shock with fatal outcome have been reported.

Administration of activated charcoal to healthy volunteers immediately or up to two hours after ingestion of amlodipine 10mg has been shown to significantly decrease amlodipine absorption.

In humans, experience with intentional overdose is limited. Gastric lavage may be worthwhile in some cases. Clinically significant hypotension due to amlodipine overdosage calls for active cardiovascular support including frequent monitoring of cardiac and respiratory function, elevation of extremities, and attention to circulating fluid volume and urine output. A vasoconstrictor may be helpful in restoring vascular tone and blood pressure, provided that there is no contraindication to its use. Intravenous calcium gluconate may be beneficial in reversing the effects of calcium channel blockade. Since amlodipine is highly protein-bound, dialysis is not likely to be of benefit.

5. Pharmacological Particulars:

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Selective Calcium Channel Blockers with mainly Vascular Effects

ATC code: C08CA01.

Amlodipine is a calcium ion influx inhibitor of the dihydropyridine group (slow channel blocker or calcium ion antagonist) and inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle.

The mechanism of the antihypertensive action of amlodipine is due to a direct relaxant effect on vascular smooth muscle. The precise mechanism by which amlodipine relieves angina has not been fully determined but amlodipine reduces total ischaemic burden by the following two actions.

Factory: UNIT 1: 13, S.V. KOIL STREET, MADHAVARAM, CHENNAI-600 060, INDIA. PHONE: +044-25530329/25531965, Email:factory@bafnapharma.com
UNIT-II : 147, Madhavaram Redhills High Road, Grantlyon Village, Vadakarai Post, Chennai-600 052. Phone:+044-26322900, E mail: fatory1@bafnapharma.com

Brand Name : Mylovasc - 5 Tablets
Generic Name : S-Amlodipine Besilate Tablets 5 mg
Module - 1

Amlodipine dilates peripheral arterioles and thus, reduces the total peripheral resistance (afterload) against which the heart works. Since the heart rate remains stable, this unloading of the heart reduces myocardial energy consumption and oxygen requirements.

The mechanism of action of amlodipine also probably involves dilatation of the main coronary arteries and coronary arterioles, both in normal and ischaemic regions. This dilatation increases myocardial oxygen delivery in patients with coronary artery spasm (Prinzmetal's or variant angina).

In patients with hypertension, once daily dosing provides clinically significant reductions of blood pressure in both the supine and standing positions throughout the 24 hour interval. Due to the slow onset of action, acute hypotension is not a feature of amlodipine administration.

In patients with angina, once daily administration of amlodipine increases total exercise time, time to angina onset, and time to 1mm ST segment depression, and decreases both angina attack frequency and glyceryl trinitrate tablet consumption.

Amlodipine has not been associated with any adverse metabolic effects or changes in plasma lipids and is suitable for use in patients with asthma, diabetes, and gout.

Haemodynamic studies and exercise based controlled clinical trials in NYHA Class II-IV heart failure patients have shown that amlodipine did not lead to clinical deterioration as measured by exercise tolerance, left ventricular ejection fraction and clinical symptomatology.

A placebo controlled study (PRAISE) designed to evaluate patients in NYHA Class III-IV heart failure receiving digoxin, diuretics and ACE inhibitors has shown that amlodipine did not lead to an increase in risk of mortality or combined mortality and morbidity with heart failure.

In a follow-up, long term, placebo-controlled study (PRAISE-2) in patients with NYHA III and IV heart failure without clinical symptoms or objective findings suggestive of underlying ischaemic disease, on stable doses of ACE inhibitors, digitalis, and diuretics, amlodipine had no effect on total cardiovascular mortality. In this same population amlodipine was associated with increased reports of pulmonary oedema despite no significant difference in the incidence of worsening heart failure as compared to placebo.

Factory: UNIT 1: 13, S.V. KOIL STREET, MADHAVARAM, CHENNAI-600 060, INDIA. PHONE: +044-25530329/25531965, Email:factory@bafnapharma.com
UNIT-II : 147, Madhavaram Redhills High Road, Grantlyon Village, Vadakarai Post, Chennai-600 052. Phone:+044-26322900, E mail: fatory1@bafnapharma.com

Brand Name : Mylovasc - 5 Tablets
Generic Name : S-Amlodipine Besilate Tablets 5 mg
Module - 1

A randomized double-blind morbidity-mortality study called the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was performed to compare newer drug therapies: amlodipine 2.5-10 mg/d (calcium channel blocker) or lisinopril 10-40 mg/d (ACE-inhibitor) as first-line therapies to that of the thiazide-diuretic, chlorthalidone 12.5-25 mg/d in mild to moderate hypertension."

A total of 33,357 hypertensive patients aged 55 or older were randomized and followed for a mean of 4.9 years. The patients had at least one additional CHD risk factor, including: previous myocardial infarction or stroke (> 6 months prior to enrollment) or documentation of other atherosclerotic CVD (overall 51.5%), type 2 diabetes (36.1%), HDL-C < 35 mg/dL (11.6%), left ventricular hypertrophy diagnosed by electrocardiogram or echocardiography (20.9%), current cigarette smoking (21.9%).

The primary endpoint was a composite of fatal CHD or non-fatal myocardial infarction. There was no significant difference in the primary endpoint between amlodipine-based therapy and chlorthalidone-based therapy: RR 0.98 95% CI(0.90-1.07) p=0.65. Among Secondary Endpoints, the incidence of heart failure (component of a composite combined cardiovascular endpoint) was significantly higher in the amlodipine group as compared to the chlorthalidone group (10.2% % vs 7.7%, RR 1.38, 95% CI [1.25-1.52] p<0.001). However, there was no significant difference in all-cause mortality between amlodipine-based therapy and chlorthalidone-based therapy. RR 0.96 95% CI [0.89-1.02] p=0.20.

In a study involving 268 children aged 6-17 years with predominantly secondary hypertension, comparison of a 2.5mg dose, and 5.0mg dose of amlodipine with placebo, showed that both doses reduced Systolic Blood Pressure significantly more than placebo. The difference between the two doses was not statistically significant.

The long-term effects of amlodipine on growth, puberty and general development have not been studied. The long-term efficacy of amlodipine on therapy in childhood to reduce cardiovascular morbidity and mortality in adulthood have also not been established.

5.2 Pharmacokinetic properties

Absorption, distribution, plasma protein binding:

Factory: UNIT 1: 13, S.V. KOIL STREET, MADHAVARAM, CHENNAI-600 060, INDIA. PHONE: +044-25530329/25531965, Email:factory@bafnapharma.com
UNIT-II : 147, Madhavaram Redhills High Road, Grantlyon Village, Vadakarai Post, Chennai-600 052. Phone:+044-26322900, E mail: fatory1@bafnapharma.com

After oral administration of therapeutic doses, amlodipine is well absorbed with peak blood levels between 6-12 hours post dose. Absolute bioavailability has been estimated to be between 64 and 80%. The volume of distribution is approximately 21 l/kg. In vitro studies have shown that approximately 97.5% of circulating amlodipine is bound to plasma proteins.

Biotransformation/elimination:

The terminal plasma elimination half life is about 35-50 hours and is consistent with once daily dosing. Amlodipine is extensively metabolised by the liver to inactive metabolites with 10% of the parent compound and 60% of metabolites excreted in the urine.

Use in the elderly:

The time to reach peak plasma concentrations of amlodipine is similar in elderly and younger subjects. Amlodipine clearance tends to be decreased with resulting increases in AUC and elimination half-life in elderly patients. Increases in AUC and elimination half-life in patients with congestive heart failure were as expected for the patient age group studied.

A population PK study has been conducted in 74 hypertensive children aged from 12 months to 17 years (with 34 patients aged 6 to 12 years and 28 patients aged 13 to 17 years) receiving amlodipine between 1.25 and 20 mg given either once or twice daily. In children 6 to 12 years and in adolescents 13-17 years of age the typical oral clearance (CL/F) was 22.5 and 27.4 L/hr respectively in males and 16.4 and 21.3 L/hr respectively in females. Large variability in exposure between individuals was observed. Data reported in children below 6 years is limited.

5.3 Pre-clinical Safety:

None.

6. Pharmaceutical Particulars:

6.1 List of Excipients:

Microcrystalline Cellulose	BP 2018
Sodium Starch Glycolate	BP 2018

Factory: UNIT 1: 13, S.V. KOIL STREET, MADHAVARAM, CHENNAI-600 060, INDIA. PHONE: +044-25530329/25531965, Email:factory@bafnapharma.com
UNIT-II : 147, Madhavaram Redhills High Road, Grantlyon Village, Vadakarai Post, Chennai-600 052. Phone:+044-26322900, E mail: fatory1@bafnapharma.com

Brand Name : Mylovasc - 5 Tablets
Generic Name : S-Amlodipine Besilate Tablets 5 mg
Module - 1

Croscarmellose Sodium	BP 2018
Crospovidone	BP 2018
Sodium Acid Citrate	BP 2018
Colloidal Anhydrous Silica	BP 2018
Magnesium Stearate	BP 2018

6.2 Incompatibilities: Nil.

6.3 Shelf Life: 36 months.

6.4 Special Precautions for storage:

Store in the original pack below 30°C. Keep out of reach of children.

6.5 Nature and contents of container:

Blister Pack (Printed Aluminum Foil –Amber PVC film) of 10 tablets, such 3 blisters are packed in primary carton along with pack insert.

6.6 Special precautions for disposal and other handling

None

7. Marketing Authorization Holder:

Registered Office:
Bafna Pharmaceuticals Ltd
No.299, Thambu Chetty Street,
Chennai – 600 001
India.

Factory Address:
No.147, Madhavaram Redhills High Road,
Grantlyon Village, Vadakarai Post,
Chennai – 600 052. India

Factory: UNIT 1: 13, S.V. KOIL STREET, MADHAVARAM, CHENNAI-600 060, INDIA. PHONE: +044-25530329/25531965, Email:factory@bafnapharma.com
UNIT-II : 147, Madhavaram Redhills High Road, Grantlyon Village, Vadakarai Post, Chennai-600 052. Phone:+044-26322900, E mail: fatory1@bafnapharma.com

8. **Marketing Authorization Number:**
   TN00002269 dated 08.12.2006

9. **Date of first Authorization /renewal of the authorization:** 08.12.2006

10. **Date of revision of text:** Apr 2019

Artworks Check List

Customer Name		**Unvanished Area**	Yes
Manufacturing facility	Grantlyon	**Mfg.Lic.No**	TN/DRUGS/TN00002269
Job Name	Mylovasc - 2.5	**Batch.No/Exp.Date**	Yes
Country	Nigeria & Kenya	**Storage Condition**	Yes
Language	English/French		Pantone 623 C
Dimension	Length(81mm) Breadth(16mm) Height(39mm)		Red
Type	Carton		Black
Style	Reverse Tuck in Flap		
Substrate	320 GSM / Cyber XL		
Mill	ITC		
Varnish / Finish	Aqueous Coating	**Printing**	Front side only
Braille / Embossing	Not Required		Carton Key line
Barcode	08906009310152	**Manufacturer Logo & Address**	Yes
Registration Code No		**Marketeer Logo & Address**	Yes
Item Code No	xxxx xxxx	**Bafna Reference file no**	Revised No: 1
Special Note		**Software used**	corel draw 13

Artist	Regulatory	Manager	QC	QA	
Sign	Sign	Sign	Sign	Sign	

Total foil size 162 mm



Artworks Check List

Customer Name		**Unvanished Area**	Yes
Manufacturing facility	Grantlyon	**Mfg.Lic.No**	TN/DRUGS/TN00002269
Job Name	Mylovasc - 2.5	**Batch.No/Exp.Date**	Yes
Country	Nigeria & Kenya	**Storage Condition**	Yes
Language	English/French		
Dimension	162mm Aluminium Foil		
Type	Foil		Black
Style	NA		
Substrate	NA		
Mill	NA		
Varnish / Finish	NA	**Printing**	Front side only
Braille / Embossing	NA		Carton Key line
Barcode	NA	**Manufacturer Logo & Address**	Yes
Registration Code No		**Marketeer Logo & Address**	Yes
Item Code No	XXXX	**Bafna Reference file no**	Revised No: 1
Special Note		**Software used**	corel draw 13

Artist	Regulatory	Manager	QC	QA	
Sign	Sign	Sign	Sign	Sign	

MYLOVASC®-2.5/5 Tablets

(S - AMLODIPINE BESILATE TABLETS 2.5 / 5 MG)

COMPOSITION:

MYLOVASC – 2.5 TABLETS:
Each uncoated tablet contains: S-Amlodipine Besilate equivalent to S-Amlodipine 2.5 mg

MYLOVASC- 5 TABLETS:
Each uncoated tablet contains: S-Amlodipine Besilate equivalent to S-Amlodipine 5.0 mg

DESCRIPTION:
S(-) Amlodipine is the pharmacologically active isomer of Amlodipine. S(-) Amlodipine is chemically designated as S(-) 3-ethyl-5-methyl-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate benzenesulphonate. Its empirical formula is CHCIN.O.C.H.O.S with the molecular weight of 567.1



MECHANISM OF ACTION:
S(-) Amlodipine is the active enantiomer of amlodipine. It blocks the passage of calcium ions into the vascular smooth muscle cells and myocardial cells during depolarisation resulting in relaxation of coronary vascular smooth muscle and coronary vasodilatation. It also helps to increase the delivery of oxygen to the myocardial tissues in patients with vasospastic angina.

PHARMACODYNAMICS:
S(-) Amlodipine, the chirally pure form of Amlodipine, is a calcium channel antagonist belonging to the dihydropyridine class. The S(-) isomer of Amlodipine is found to possess greater pharmacological effects than R(+) Amlodipine. S(-) Amlodipine is 1000 times more potent than the R(+) isomer in binding to the dihydropyridine receptor. In humans, the dominant effects of Amlodipine are consuquent to vasodilation. S(-) Amlodipine lowers peripheral vascular resistance without causing a reflex tachycardia. It is effective as a once daily dosage in the control of hypertension.

PHARMACOKINETICS AND METABOLISM:
Administration of S(-) Amlodipine 2.5mg as a single dose in the fasting state produced maximum plasma concentration (C_{max}) of 8.30 ± 1.071 ng/ml in 2.73 ± 0.88 hrs. (T_{max}). Amlodipine is extensively (about 90%) converted to inactive metabolites via hepatic metabolism with 10% of the parent compound and 60% of the metabolites excreted in urine. Ex vivo studies have shown that approximately 93% of the circulating drug is bound to plasma proteins in hypertensive patients. The mean AUC 0-t value (t=48 hrs) of tablets S(-) Amlodipine (2.5mg) is 95.33 ± 14.45ng.hr/ml. The AUC 0-∞ value is recorded to be 140.91 ± 28.06ng.hr/ml. The plasma elimination half life of S(-) Amlodipine has been found to be 31.09 ± 12.65hrs.

INDICATIONS:
Hypertension: Mylovasc (S-Amlodipine Besilate) tablet is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.

DOSAGE:
The normal recommended dose is 2.5mg once a day for the treatment of hypertension. Based on the clinical response of the patient, the dose may be enhanced, upto 5mg once a day.

Manufactured for:
Prisma Pharma FZE
P. O. Box 17269
Jebel Ali Free Zone
Dubai, U.A.E.

ADMINISTRATION:
Take this medication by mouth, usually once daily with or without food or as directed by your doctor.

CONTRAINDICATION:
Mylovasc is contraindicated in patients with liver insufficiency and pregnancy. Hypersensitivity to any of the component of the formulation.

ADVERSE EFFECTS:
On the basis of clinical data available, the following adverse events have been reported in less than 2% of patients: vertigo (0.05%), tachycardia (0.05%), cough (0.05%), headache (0.43%), difficulty in breathing (0.1%), edema (0.75- 1.92%), cheerlessness (0.05%) and facial puffiness (0.05%). These side effects were mild in nature.

PRECAUTION:
No controlled clinical study of S(-) Amlodipine has been performed in patients with hepatic impairment and renal impairment. Clinical studies in patients with normal liver function have shown that there is no elevation in the hepatic enzymes with the use of S(-) Amlodipine. However, caution should be taken while administering S(-) Amlodipine to patients with hepatic and renal impairments.

PREGNANT WOMEN AND NURSING MOTHER:
There is no data available on the use of S(-) Amlodipine in pregnant and lactating women, hence the drug should be administered only when the potential benefits outweighs the risk to the patients.

CHILDREN:
Safety and effectiveness of this product in children has not been established.

DRUG INTERACTIONS:
Clinical studies have shown that S(-) Amlodipine when combined with aspirin, nitrates, beta-blockers, statins, ACE inhibitors, H2 blockers and proton pump inhibitors produced no drug interactions.

OVERDOSAGE:
There are no reported case of overdosage with the use of S(-) Amlodipine. Overdosage with racemic Amlodipine may cause excessive peripheral vasodilation with marked hypotension and possible a reflex tachycardia. Hence caution should be taken in case of an overdosage with S(-) Amlodipine. If massive overdose occurs, active cardiac and respiratory monitoring should be instituted. Frequent blood pressure measurements should be performed. If hypotension occurs, cardiovascular support including elevation of the extremities and the iudious administration of fluids be initiated. If hypotension remains unresponsive to these conservative measures, administration of vasopressors (such as phenylephrine) should be considered with attention to the circulating drug. If massive overdose occurs, gastric lavage should be employed. As this product is highly plasma protein bound, haemodialysis is not likely be of benefit.

STORAGE:
Store in the original package below 30°C. Keep out of the reach of children. Store away from heat and direct light.

MEDICINE CLASSIFICATION:
Prescription Medicine

PRESENTATIONS:
Blister Packing: 3 x 10 Tablets.

Mfg. Lic. No:
TN/DRUGS/TN00002269

Manufactured by:
Bafna Pharmaceuticals Ltd.
147, Madhavaram Redhills High Rd
Grantlyon Village
Chennai - 600052, India

PRISMA®
A RAY OF HOPE

xxxx xxxx

Artworks Check List

Customer Name		**Unvanished Area**	Yes
Manufacturing facility	Grantlyon	**Mfg.Lic.No**	TN/DRUGS/TN00002269
Job Name	Mylovasc - 2.5/5	**Batch.No/Exp.Date**	Yes
Country	Nigeria & Kenya	**Storage Condition**	Yes
Language	English/French		
Dimension	Height (212mm) x Length (140mm)		
Type	Leaflet		Black
Style	NA		
Substrate	NA		
Mill	NA		
Varnish / Finish	NA	**Printing**	Front side only
Braille / Embossing	NA		Carton Key line
Barcode	NA	**Manufacturer Logo & Address**	Yes
Registration Code No		**Marketeer Logo & Address**	Yes
Item Code No	xxxx xxxx	**Bafna Reference file no**	Revised No: 1
Special Note		**Software used**	corel draw 13

Artist	Regulatory	Manager	QC	QA	
Sign	Sign	Sign	Sign	Sign	